Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 5 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
A slowdown in healthcare demand due to product price increases and the ongoing domestic inflationary trend, reviews of transaction terms and other conditions accompanying consolidation and realignment among retail companies, delays in passing on price increases for products handled by the company, higher logistics costs, increased upfront investment costs for digitalization and systems implementation, and temporary costs associated with the relocation of the head office.
| Item | Details |
|---|---|
| Net Sales | ¥364,000 million → ¥360,358 million（-1.0%） |
| Operating profit | ¥3,094 million → ¥719 million（-76.8%） |
| Ordinary income | ¥4,368 million → ¥1,964 million（-55.0%） |
| Profit attributable to owners of the parent | ¥3,058 million → ¥1,339 million（-56.2%） |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 5 February 2026 |
| Previous-period results | Revenue: ¥349,452 million; operating profit: ¥2,768 million; ordinary profit: ¥3,991 million; net income attributable to owners of the parent: ¥2,639 million (fiscal year ended March 2025) |
| Reason for the revision | A slowdown in healthcare demand due to product price increases and the ongoing domestic inflationary trend, reviews of transaction terms and other conditions accompanying consolidation and realignment among retail companies, delays in passing on price increases for products handled by the company, higher logistics costs, increased upfront investment costs for digitalization and systems implementation, and temporary costs associated with the relocation of the head office. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited a slowdown in healthcare demand due to product price increases and the ongoing domestic inflationary trend, reviews of transaction terms and other conditions accompanying consolidation and realignment among retail companies, delays in passing on price increases for products handled by the company, higher logistics costs, increased upfront investment costs for digitalization and systems implementation, and temporary costs associated with the relocation of its head office.